OBJECTIVE—To review the effects of monotherapy with α-glucosidase inhibitors (AGIs) for
patients with type 2 diabetes, with respect to mortality, morbidity, glycemic control, insulin …

Background Alpha‐glucosidase inhibitors such as acarbose or miglitol, have the potential to
improve glycemic control in type 2 diabetes mellitus. The true value of these agents …

Abstract α‐Glucosidase inhibitors produce a significant reduction of postprandial
hyperglycemia and postprandial insulin with a significant decrease of HbA1c (∼ 0.7%), by …

Purpose Dyslipidemia, characterized by elevated levels of triglycerides (TG), low-density
lipoprotein (LDL), total cholesterol (TC), and reduced levels of high-density lipoprotein …

Acarbose (ACB) seems to be an effective drug in the management of cardiovascular risk
factors. However, no previous meta-analysis of randomized controlled trials (RCTs) has …

Although most commonly used drugs such as biguanides, sulfonylureas, and more recently,
thiazolidinediones, are effective in controlling fasting hyperglycemia, a high percentage of …

Background A carbose is the first of a new class of antidiabetic agents, the α-glucosidase
inhibitors. This study characterizes and identifies predictors of persistence of use of …

The aminocyclitol family of natural products is a class of sugar-derived microbial secondary
metabolites that demonstrate significant biological activities. Within this class of natural …

Alpha‐glucosidase inhibitors are oral antidiabetic medications that delay the digestion of
complex carbohydrates by acting as competitive inhibitors of intestinal α‐glucosidases. By …

The objective of this study was to investigate the efficacy, tolerability, and safety of acarbose
in the improvement of glycemic control in Asian patients with type 2 diabetes inadequately …